REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Replimune Group, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Replimune Group, Inc. due to a class action complaint alleging breaches of fiduciary duties by the board of directors during the specified class period [1][2]. Group 1: Lawsuit Details - The lawsuit claims that defendants made false and misleading statements regarding the IGNYTE trial, which the FDA deemed inadequate and not well-controlled [2]. - It is alleged that the defendants overstated the trial's prospects, leading to materially false and misleading statements about Replimune's business and operations [2]. Group 2: Next Steps for Investors - Long-term stockholders of Replimune are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and the ongoing investigation [3]. - The firm offers a no-cost consultation for investors seeking to understand their legal options [3]. Group 3: About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents investors in complex litigation across various courts in the United States [4].